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Abstract

Author Manuscript

Gallotannins containing a glucitol core, which are only produced by members of the maple (Acer)
genus, are more potent α-glucosidase inhibitors than the clinical drug, acarbose. While this
activity is influenced by the number of substituents on the glucitol core (e.g. more galloyl groups
leads to increased activity), the mechanisms of inhibitory action are not known. Herein, we
investigated ligand-enzyme interactions and binding mechanisms of a series of ‘glucitol-core
containing gallotannins (GCGs)’ against the α-glucosidase enzyme. The GCGs included ginnalins
A, B and C (containing two, one, and one galloyl/s, respectively), maplexin F (containing 3
galloyls) and maplexin J (containing 4 galloyls). All of the GCGs were noncompetitive inhibitors
of α-glucosidase and their interactions with the enzyme were further explored using biophysical
and spectroscopic measurements. Thermodynamic parameters (by isothermal titration calorimetry)
revealed a 1:1 binding ratio between GCGs and α-glucosidase. The binding regions between the
GCGs and α-glucosidase, probed by a fluorescent tag, 1,1′-bis(4-anilino-5-napththalenesulfonic
acid, revealed that the GCGs decreased the hydrophobic surface of the enzyme. In addition,
circular dichroism analyses showed that the GCGs bind to α-glucosidase and lead to loss of the
secondary α-helix structure of the protein. Also, molecular modeling was used to predict the
binding site between the GCGs and the α-glucosidase enzyme. This is the first study to evaluate
the mechanisms of inhibitory activities of gallotannins containing a glucitol core on α-glucosidase.
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Evaluation of the mechanisms of inhibitory activities of gallotannins containing a glucitol core
(GCGs) on α-glucosidase.
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INTRODUCTION
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In mammals, enzymes involved in the carbohydrate metabolic pathways have been the
therapeutic targets for various diseases, including diabetes, cancer, and viral infections.1–3
Among these enzymes, the group of glucosidases (EC 3.2.1.20) plays a crucial role in
carbohydrate metabolism by catalyzing the cleavage of glycosidic linkages of
oligosaccharides or glycoconjugates to release mono-saccharides.4 Inhibition of glucosidase
hinders glucose absorption and consequently decreases postprandial blood glucose levels.
Development of α-glucosidase inhibitors, as a class of antidiabetic medications for type II
diabetes mellitus (T2DM), has attracted significant scientific attention.5 In fact, several
synthetic α-glucosidase inhibitors (AGIs), including acarbose, miglitol, and voglibose, are
widely used as clinical treatment options for T2DM.6, 7 However, adherence to synthetic
AGIs, as prescription medications, has suffered due to prominent undesirable adverse
effects, including flatulence, diarrhea, and abdominal pain.8 In addition, the adult dose of
some AGIs, for instance, acarbose, can range from 25–100 mg taken orally 3 times daily.
Therefore, the utilization of natural products represents an attractive alternative to clinical
drugs since they may lead to increased patient compliance. Moreover, naturally occurring
AGIs, isolated from medicinal plants and medicinal foods, offer an attractive dietary
strategy for T2DM management since they tend to be safe, and have fewer adverse effects
than synthetic AGIs.9
The maple (Acer) genus is widely regarded for certain species including the sugar maple
(Acer saccharum) and red maple (Acer rubrum) species, the sap of which are collected and
concentrated to produce the natural sweetener, maple syrup.10 Interestingly, in the plant
kingdom, only members of the maple (Acer) genus are reported to produce gallotannins
containing a glucitol instead of a glucose core which is most commonly found in
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gallotannins.11–16 Our group and others have shown that these ‘glucitol-core containing
gallotannins (GCGs)’ display potent α-glucosidase inhibitory properties which is influenced
by the number, type, and location of substituents on their glucitol core.14–17 In addition, our
group showed that a red maple bark extract, enriched in GCGs, was similar in activity as
acarbose, in lowering blood glucose in an animal model.18 Therefore GCGs represent an
interesting polyphenol sub-class of plant natural products which show great promise as
natural AGIs.

Author Manuscript

In our group’s research efforts to identify natural AGIs, we reported on a series of new
GCGs, named maplexins E-I, from the red maple (Acer rubrum) species.14–16 The GCGs
feature different numbers and positions of galloyl groups attached to a 1,5-anhydro-Dglucitol core and exhibited 20-fold higher potency than acarbose which increased with the
number of galloyl groups on the glucitol moiety. However, since these naturally occurring/
isolated GCGs only contained three galloyl groups at the most, in an effort to broaden our
test panel of GCGs, we synthesized a tetragalloylglucitol analog19 (details provided in
Online Supplementary Material) assigned the common name of maplexin J. Indeed,
maplexin J was found to be three times more potent than maplexins E and F (contain
trigalloyls), and 70 times more potent than acarbose (see Table 1), confirming our previous
SAR observations. In the current study, we have focused our attention on investigating the
mechanisms of inhibitory actions of these GCGs on the α-glucosidase enzyme. This
research project was also prompted, in part, by the fact that other natural AGIs, such as 1deoxynojirimycin, resveratrol, and oxyresveratrol, show different mechanisms of action
against α-glucosidase.20, 21

Author Manuscript

The mechanisms of inhibition of compounds on the α-glucosidase enzyme can be
investigated by several biophysical methods including binding domains, modifications of
hydrophobic surfaces, and secondary structural conformational changes of enzymes induced
by binding ligands.21 In this study, enzymatic kinetics and biophysical tools, including
isothermal titration calorimetry (ITC), fluorescence, and circular dichroism (CD)
spectroscopic methods, were used to elucidate the inhibitory mechanisms of the GCGs
against the α-glucosidase enzyme. Computational manipulation of homology modeling and
molecular docking were performed to support the prediction of binding actions between the
GCGs and the α-glucosidase enzyme.

EXPERIMENTAL SECTION
Chemicals

Author Manuscript

α-Glucosidase (EC 3.2.1.20) from Saccharomyces cerevisiae, p-Nitrophenyl-α-Dglucopyranoside (pNPG), and bis-8-anilinonaphthalene-1-sulfonate (bis-ANS) were
purchased from Sigma Aldrich (St. Louis, MO). All other chemicals were analytical reagent
grade and were purchased from Sigma Aldrich, unless otherwise specified. The naturally
occurring GCGs (Figure 1): ginnalin A (GA; contains two galloyls), ginnalin B (GB;
contains one galloyl), ginnalin C (GC; contains one galloyl) and maplexin F (MF; contains
three galloyls) were isolated from the red maple species as previously reported.14, 15
Maplexin J (MJ; contains four galloyls) was synthesized in our laboratory according to
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modifications of a previously published method19 [details provided in Online Supporting
Material].
Measurements of α-glucosidase inhibitory assay

Author Manuscript

A mixture of 50 μL test samples and 100 μL 0.1 M phosphate buffer (pH 6.9) containing
yeast α-glucosidase solution (1.0 U/ml) were incubated in 96-well plates at 25 °C for 10
minutes. After pre-incubation, 50 μL of 5 mM p-nitrophenyl-α-D-glucopyranoside solution
in 0.1 M phosphate buffer (pH 6.9) were added to each well at timed intervals. The reaction
mixtures were incubated at 25 °C for 5 minutes. Before and after incubation, absorbance
was recorded at 405 nm by a micro-plate reader (SpectraMax M2, Molecular Devices Corp.,
operated by SoftmaxPro v.4.6 software, Sunnyvale, CA) and compared to that of the control
which had 50 μL buffer solutions in place of the samples. The α-glucosidase inhibitory
activity was expressed as inhibition % and was calculated as: Inhibition% = 100 × [(C5 −
C0) − (S0 − S0)] / (C5 − C0), where C0 is the absorbance of the reagent blank in 0 minute, S0
the absorbance of the samples in 0 minute, C5 the absorbance of the reagent blank in 5
minutes, and S5 the absorbance of the samples in 5 minutes.22
Kinetics of α-glucosidase inhibition

Author Manuscript

The inhibition types of ginnalin A (GA), maplexin F (MF), and maplexins J (MJ) were
determined from Lineweaver–Burk plots, using previously reported methods with minor
modifications.23 Typically, two concentrations around the IC50 values of each sample were
chosen (ranging from 2 – 250 μM). For each concentration, α-glucosidase activities were
tested by using different concentrations of pPNP glycoside (1 to 1000 μM). The mixtures of
the enzyme and the inhibitor were dissolved in 50 mM phosphate buffer (pH 6.8), and preincubated at room temperature for 30 minutes, and then the substrate was added. The
enzymatic reaction was carried out at room temperature for 60 seconds, and monitored
spectrophotometrically by measuring the absorbance at 405 nm. Inhibition types of the
inhibitors were determined by Double-reciprocal plots.
Titration microcalorimetry
Isothermal titration calorimetry (ITC), used to determine the thermodynamic properties
between the GCGs and α-glucosidase, were measured with a VP-ITC

Author Manuscript

Microcalorimeter (MicroCal, Northampton, MA, USA) according to previously reported
methods with modifications.24 A typical titration experiment consisted of 17 consecutive
injections at 240 s intervals consisting of 14 μL injections of each GCGs into the titration
cell at 25 °C in phosphate buffer (pH 7.0, 100 mM). The titration cell was stirred
continuously at 310 rpm. The GCGs (1 – 4 mM) and α-glucosidase enzyme (0.026 – 0.031
mM) were dissolved in the same phosphate buffer and degassed for 20 mins under vacuum
using a ThermoVac (MicroCal, Northampton, MA, USA) prior to each experiment. Controls
included buffer injected into buffer and GCGs injected into buffer solutions, respectively.
Data were analyzed by using nonlinear regression with a single-site binding model in VP
Viewer 2000, which uses the scientific plotting software, ORIGIN 7 (Origin Lab. Corp.,
Northampton, MA, USA).
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α-glucosidase (2 μM) was incubated in the presence of various concentrations of the GCGs
(0–80 μM) at 37 °C for 5 minutes. Bis-ANS (5 μM) was then added, and fluorescence was
measured after incubation at 37 °C for 15 minutes (λex = 400 nm, λem = 440–600 nm).25
Circular dichroism (CD) spectroscopy

Author Manuscript

Homology modeling of α-glucosidase

Author Manuscript

Far UV CD measurements (190–240 nm) were conducted on a Jasco J-810
spectropolarimeter equipped with a Peltier temperature controller at 25 °C. Briefly, 2 μM of
α-glucosidase was treated with various concentrations of the GCGs (0–80 μM). The samples
were dissolved in 200 μL of a sodium phosphate buffer (0.1 M, pH 6.8) and placed in a 1.0
mm path length cell. The spectra were collected and corrected by subtraction of a blank 0.1
M sodium phosphate buffer (pH 6.8), reducing noise and smoothing.26 The changes of
secondary structure of α-glucosidase were estimated according to a method in the
DichroWeb program, an online server for protein secondary structure analyses from the CD
spectroscopic data.27, 28

Refinement of 3D α-glucosidase structure

The Saccharomyces cerevisiae α-glucosidase was downloaded from the UniProt protein
knowledgebase (accession number P53341).29 The structure of isomaltase from
Saccharomyces cerevisiae (PDB entry 3A4A) that shared a 71.8% sequence identity and
87.1% sequence similarity with Saccharomyces cerevisiae α-glucosidase based on National
Center for Biotechnology Information Basic Local Alignment Search Tool (NCBI BLAST)
search results was selected as the template for homology modeling. Sequence alignment and
structural model building were performed using DS 3.5 (Discovery Studio, version 3.5,
Accelrys, Inc., San Diego, CA, USA). Ten initial 3D α-glucosidase structures were
constructed and sorted in ascending order of PDF total energy score. The best structure with
the most negative score was selected for further refinements.

Molecular dynamics (MD) simulation is widely used for both homology and X-ray
structural refinement.30, 31 The initial best 3D α-glucosidase structure from homology
modeling was refined through MD simulations using Amber12.32 The initial structure was
solvated in an octahedron periodic box (based on the TIP3P model) with 12 Å of water
along each dimension. The protein was applied with the Amber ff99SB force field and
counterions were added to the system to neutralize charges.33

Author Manuscript

MD simulations consisted of energy minimization, heat phase, equilibration, and production.
The solvated system was minimized by three steps. First, a harmonic constraint potential of
10 kcal/mol/Å2 was applied to all atoms except water molecules. Second, the protein
backbone atoms were restrained with a force of 5.0 kcal/mol/Å2. Finally, all atoms were
allowed to move freely. In each step, energy minimization was executed by the steepest
descent method for the first 2000 steps and the conjugated gradient method for the
subsequent 2000 steps. After minimization, the system was gradually heated in the canonical
“NVT ensemble” from 0 to 300 Kelvin (K) in 100 picoseconds (ps) using a Langevin
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thermostat with a coupling coefficient of 1.0 ps with a force constant 10 kcal/mol/Å2 on the
protein. The system was then equilibrated for the first two 500 ps and subsequent three 200
ps at 300 K with decreasing restraint weights reduced from 10 to 0.2 kcal/mol/Å2. A
production simulation run for 10 ns was lastly performed at 300 K. During the MD
simulations, the long-range Coulombic interactions were handled using the particle mesh
Ewald (PME) method and the cutoff distance for the long-range van der Waals (vdW)
energy term was set at 10.0 Å.34 All hydrogen atoms were constrained using the “SHAKE”
algorithm and the time step was set at 2 femtosecond. Coordinate trajectories were recorded
every 2 ps. The refined 3D α-glucosidase structure was obtained from last snapshot of MD
simulations and validated by Profiles-3D Verify module in DS 3.5.
Molecular docking

Author Manuscript

GA, MF, and MJ were optimized using MMFF94s force field. The refined α-glucosidase
structure from MD simulations was protonated based on amber99 force field after removing
water molecules. To obtain the most plausible binding sites, we searched the whole 3-D
space of the receptors, including both the active-site (Asp214, Glu276 and Asp349) and nonactive-site regions. Site Finder module encoded in MOE (MOE 2010.10. Chemical
Computing Group, Inc. Montreal, Canada) was employed for detecting potential ligand
binding sites of α-glucosidase. MOE-docking was employed to identify the binding poses of
GA, MF, MJ and α-glucosidase. During docking study, 30 poses per compound were
retained. All docked poses of GA, MF, and MJ were ranked on the basis of the binding
docking energies according to LondondG score.35, 36 The best conformation for each
compound from clustering results was chosen for binding mode analyses.

RESULTS
Author Manuscript

Comparison of α-glucosidase inhibitory effects of GCGs
As shown in Table 1, the inhibitory activities of the GCGs against the α-glucosidase enzyme
increased with increasing number of galloyl groups attached to the 1,5-anhydro-D-glucitol
moiety. The mono-galloyl substituted gallotannins (GB and GC) did not demonstrate any
inhibitory activities on α-glucosidase (IC50 > 1000 μM), and the di-galloyl gallotannin (GA)
only showed a moderate inhibitory activity with an IC50 value of 216.43 μM. However, the
activities of MF and MJ, which contain three and four galloyl groups, respectively, were
significantly enhanced (IC50 = 13.70 and 4.27 μM, respectively). The results indicated that
MF and MJ were potent α-glucosidase inhibitors.

Author Manuscript

To further evaluate the inhibitory characteristics of GA, MF and MJ, enzyme kinetic assays
were performed and their inhibition types were determined by the Lineweaver-Burk plots
(Figure 3). The Lineweaver-Burk plot of each GCG (at different concentrations ranging
from 2 – 250 μM) generated straight lines that all intersected the X-axis at the same point,
suggesting that the GCGs were typical noncompetitive inhibitors of α-glucosidase.
Therefore, this implied that GA, MF, and MJ bind to the noncompetitive site of the yeast’s
α-glucosidase enzyme rather than to the catalytic domain of the enzyme.
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The thermodynamic properties of the binding interaction between the GCGs and αglucosidase complex were determined by using ITC. The titration peaks of GA, GB, and GC
(at concentrations ranging from 1 – 4 mM) were too weak to yield thermodynamic
parameters. However, the titration peaks for MF or MJ (concentrations ranging from 1 – 2
mM) showed binding interactions that were typically exothermic (see Figure 3). The
thermodynamic parameters for GA, MF, and MJ, obtained from the ITC analyses, are
summarized in Table 2. Both MF and MJ had a ligand:enzyme ratio (N value) of 1:1
indicating that one molecule of each of these GCGs binds to one molecule of the enzyme.37
In addition, the binding constants (Ka) of MF or MJ with α-glucosidase were 2.85 × 104 and
4.22 × 104 mol−1, respectively. The stronger binding affinity of MJ with α-glucosidase,
compared to that of MF and the enzyme, was in agreement with the results obtained from
the α-glucosidase inhibitory assay with these GCGs (Table 1).38 The negative ΔG values for
both MF and MJ (−6.09 and −6.31 kcal/mol, respectively) suggested that their binding
interactions were spontaneous.38, 39 Furthermore, a positive ΔS value and a negative ΔH
value for both MF and MJ indicated that their binding interactions with the α-glucosidase
enzyme were enthalpy-driven.39, 40 Notably, the thermodynamic parameters observed for
MF and MJ are similar to those reported for the major gallotannin present in tea, namely,
epigallocatechin gallate (EGCG), with lipase.38
Given that a positive ΔS value may be associated with the first stage of binding
interaction,41, 42 where the ligand and enzyme are immobilized in a hydrophobic
environment, we further examined the hydrophobic alteration of the α-glucosidase enzyme.
GCGs reduced the hydrophobicity of α-glucosidase

Author Manuscript
Author Manuscript

Noncovalent fluorescent probes have been extensively used for the study of protein
conformation.43, 44 An external fluorescent probe such as bis-8-anilinonaphthalene-1sulfonate (bis-ANS) is sensitive to the protein microenvironment and selectively binds to the
hydrophobic surface of protein.45 Therefore, a bis-ANS probe was utilized to assess the
exposure of α-glucosidase hydrophobic surface induced by the ligands. As shown in Figure
4, after being co-incubated with α-glucosidase for 20 min at 37 °C, GA, MF, and MJ were
able to decrease the fluorescence of the bis-ANS-enzyme complex in a concentrationdependent manner. Although GA slightly decreased the fluorescent intensity of the bisANS-enzyme complex at the low concentration (20 μM), compared to the non-treatment
group, the fluorescence of the MF and MJ treatment groups were significantly reduced.
Moreover, all three ligands greatly decreased the fluorescence at concentration of 80 μM,
suggesting that GA, MF, and MJ could decrease the hydrophobic surfaces of α-glucosidase.
Since hydrophobic surface is crucial to facilitate the formation of the enzyme active site,
GA, MF, and MJ could have possibly inhibited the α-glucosidase enzyme activity by
inducing poor hydrophobic surfaces on the enzyme structure.46
Change in conformation of α-glucosidase induced by GCGs
To further examine the effects of the GCGs on the secondary structure of α-glucosidase,
circular dichroism (CD) spectra of free α-glucosidase and ligand-α-glucosidase complex
were acquired. In Figure 5, the CD spectra of the free α-glucosidase enzyme exhibited two
RSC Adv. Author manuscript; available in PMC 2016 March 15.
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characteristic negative bands at 208 and 222 nm, indicating that the major secondary protein
structure presented in the α-glucosidase was α-helix.47, 48 When various concentrations (20
– 80 μM) of the GCGs were co-incubated with α-glucosidase, the CD spectra of the ligandenzyme complex was significantly altered indicating that the conformation of the enzyme
protein was affected by the ligands in a concentration-dependent manner. As summarized in
Table 3, the GCGs bind to the enzyme protein that mainly resulted in the loss of α-helix
conformation. When 40 μM of MF and MJ were delivered to α-glucosidase, the enzyme lost
4.9 and 5.6 % of its α-helix conformation, respectively, which could potentially cause the
loss of biological functions of the α-glucosidase enzyme.
Homology modeling

Author Manuscript

Lacking the 3D structure of Saccharomyces cerevisiae α-glucosidase used in biological
assays, we constructed a 3D homology structure of α-glucosidase by computational
approach. The 3D homology models of α-glucosidase were generated with the MODELER
module in DS 3.5, and the best model with lowest PDF total energy score was refined by
10ns MD simulations (Figure 6B). Trajectory-based analysis showed that the root-meansquare deviation (RMSD) of the protein backbone atoms with reference to the initial
structural coordinates increased slowly in the first 4 nanoseconds (ns) and then subsequently
stabilized after 4 ns, suggesting that the α-glucosidase structure was stable.

Author Manuscript

The refined structure from the last snapshot of MD simulations was validated via
Profile-3D, Procheck, and Prostat analysis. The overall self-compatibility score generated by
Profile-3D module in DS 3.5 for this refined model was 252.5 (the verified expected high
score was 263.47, and the verified expected low score was 118.56). Procheck was used to
calculate the ϕ and ψ angles (Figure 6A) and four residues (Ser331, Glu522, Arg543, and
Tyr372) were located in un-allowed regions, and the percentage of residues within the
Ramachandran plot’s allowed regions was 99.32 %. Prostat analysis showed that almost all
bond lengths, angles, and torsions stayed within a rational range. All of these validation
results proved that the refined model is reliable.
Binding modes analyses

Author Manuscript

A total of 35 potential ligand binding sites of the refined model were obtained from Site
Finder module in MOE. The largest five binding sites (size > 100) were selected for the
docking study (Figure 6). As shown in Table 4, the three GCGs, namely, GA, MF, and MJ,
shared the same scaffold, suggesting that they bind at the same site for a given target. Sites
2, 4, and 5 were not suitable for these compounds because the trends of the docking scores
for GA, MF, and MJ were inconsistent with the corresponding enzyme assay results. For
example, compound MF in binding site 4 with a docking score of −17.37 Kcal/mol is lower
than that of compound MJ (−15.03 Kcal/mol) which is inconsistent with their enzyme
inhibition values (13.70 μM for MF and 4.27 μM for MJ). Similar trends were observed in
the docking results of binding sites 2 and 5.
As shown in Figure 7C, binding site 3 was located at two helix structures and the three
GCGs showed considerable binding modes based on the docking score and the enzyme
inhibition assay. As previous studies have suggested that the helix structure could be
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stabilized by targeting compounds with polyhydroxyl groups,21, 23, 49 our CD results suggest
that the helix structures were reduced with increasing concentrations of GA, MF, and MJ.
Therefore, this implied that binding site 3 is not targeted by these GCGs.

Author Manuscript

Binding site 1 is surrounded by coil, bend, and sheet structures, with little helix structures,
which contain both active and inactive sites (Figure 7A). The trends of docking score of GA,
MF, MJ, and the enzyme assay results are consistent. Based on all of the above analyses, the
GCGs, GA, MF, and MJ target the binding site 1 of Saccharomyces cerevisiae αglucosidase. The active site of α-glucosidase is comprised of Asp214, Glu276 and Asp349
and is represented by the red oval in Figure 8D. Superimposition of the binding modes of
GA, MF, and MJ suggested that all of the binding sites are located at the noncompetitive
domain of α-glucosidase (Figure 8A, B, and C), which are relatively close to the active site
(Figure 8D). All of the docking results demonstrate that GA, MF, and MJ are
noncompetitive inhibitors, in accordance with the aforementioned kinetic results (Figure 2).

Author Manuscript

As shown in Figure 8A, the hydroxyl group of GA can form two hydrogen bonds with the
side chain of Ser244 and Phe157. One galloyl group of GA is inserted in the polar area
comprised of Arg312, Glu304, Arg439, and Gln350, suggesting that a polar interaction can
be formed. Moreover, the phenyl group can form favorable hydrophobic interactions with
the side chains of Phe158, Phe157, His239, and His279. Compounds MF and MJ contain
more galloyl groups than GA, suggesting that more favorable binding interactions will be
formed against a given target according to Ge and coworkers’ results.50 As shown in Figures
8B and 8C, MF can form four hydrogen bonds with Asp408, Glu304, Ser244, and Phe157,
whereas MJ can form eight hydrogen bonds with Glu304, Ser244, Ser299, Glu276, Arg212,
Thr215, and Ala216. Thus, hydrogen bonds are formed via the hydroxyl groups of these
GCGs. Notably, a similar phenomenon has been observed in other phenolic compounds such
as xanthone derivatives,23 resveratrol, and oxyresveratrol.21 Moreover, more favorable
hydrophobic interactions are formed between MF and MJ and α-glucosidase residues
(Phe157, Phe158, Leu237, His239, His279 Phe300, and Ala278 for MF, and Phe157,
Pro309, Leu237, His239, Leu218, His279, and Arg312 for MJ). These hydrophobic sites
were occupied by GCGs, suggesting that the GCGs decreased the hydrophobic surface of
the enzyme which was consistent with the data obtained from the bis-ANS assay. Also, the
binding energy of GA, MF, and MJ is −10.45, −13.02, and −16.35 kcal/mol, respectively,
which was in full accordance with results from the enzyme inhibition assay and binding
model analyses.

DISCUSSION
Author Manuscript

The red maple (Acer rubrum) species is endemic to eastern North America and widely
known for its tree sap which is used to produce the natural sweetener, maple syrup. This
plant has also been used by the Native Americans as an herbal medicine, and recent
phytochemical and biological studies from our group on this species led to the discovery of
several GCGs.14–16 More importantly, these GCGs show potential as natural AGIs based on
in vitro and animal studies.14–16, 18 While several of these GCGs showed far more potent αglucosidase inhibitory activities than the clinical drug, acarbose, their mechanisms of action
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remained unknown. Herein, we reveal several key mechanisms by which these GCGs
interact with α-glucosidase.

Author Manuscript

First, the inhibition type of the GCGs against the α-glucosidase enzyme was found to be
noncompetitive, suggesting that these gallotannins bind to the specific site of enzymesubstrate complex rather than the enzyme catalytic domain. This binding pattern is in
agreement with previous studies of a ‘glucose-core containing gallotannin’, namely,
pentagalloyl glucose (PGG), which is also a noncompetitive α-glucosidase inhibitor.51 It is
noteworthy that this distinguishes the GCGs from acarbose, a synthetic AGI, which is
known to be a competitive inhibitor that directly binds to the active site of α-glucosidase.52
In addition, increasing the number of galloyl groups on the glucitol core enhanced the αglucosidase inhibitory activities of these GCGs, an SAR effect that has also been observed
in glucose-core containing gallotannin α-glucosidase inhibitors, namely, PGG and its
analogs.51
Second, ITC analyses revealed that the binding stoichiometry between the GCGs (MF and
MJ) and α-glucosidase was in a 1:1 ratio suggesting a single binding site for these
compounds. This data is similar to that reported for the tea gallotannin, epigallocatechin
gallate (EGCG) and lipase.38 Additionally, the thermodynamic parameters (Table 2)
revealed that the formation of the ligand-enzyme complex was spontaneous and enthalpydriven suggesting that the binding interaction was largely attributed to the hydrogen
bonding. This is not surprising since it has been well established that gallotannins form
hydrogen bonds with the polar residues of proteins through their galloyl and/or hydroxyl
groups.53, 54 This observation was further supported by our computational models.
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Given that gallotannins-protein binding can be enthalpy-driven (by hydrogen bonding and
protonation),55–57 entropic factors (such as hydrophobic interactions),41 are also often
involved in the formation of ligand-protein complexes. Therefore, we examined the
hydrophobicity of the GCGs and α-glucosidase complex.
The GCGs reduced the hydrophobic surface of the enzyme and impeded the formation of the
active center of the α-glucosidase enzyme. GA, MF, and MJ significantly decreased the αhelix conformation of the enzyme protein. Since α-helix is a rigid secondary structure that
maintains many enzymatic protein functions, loss of this structure may result in enzyme
destabilization. Therefore, the major inhibitory mechanism of the GCGs against αglucosidase mainly consists of binding to the enzyme-substrate complex, reducing the
hydrophobic surface, and changing the α-helix conformation of the enzyme protein.
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Lastly, the GCGs act as noncompetitive inhibitors that bind to a noncompetitive domain of
α-glucosidase located at relatively close to the active site (Figure 7D). This noncompetitive
domain is different from the binding pocket of acarbose (competitive inhibitor).52 The
predicted noncompetitive binding site may provide a novel site for structure-based
discovering and designing novel α-glucosidase inhibitors. The molecular docking results
demonstrate that more galloyl groups in the GCGs leads to enhanced binding affinity against
α-glucosidase. A major challenge remains for the studies of α-glucosidase enzyme chemical
steps by multiscale simulation and this methodology has been developed.58 Therefore,
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further in silico studies to investigate the aforementioned parameters, as well as multiscale
dynamic mechanisms of whether GCGs could trigger the loss of the secondary α-helix of
the flexible structures (binding sites of GCGs), is warranted and included in our group’s
future studies.
Therefore, overall, this study provides useful information on these GCGs which can be used
to guide the design of new GCG analogs with superior activities against α-glucosidase.

CONCLUSION

Author Manuscript

In summary, we have determined the inhibition type of ‘glucitol-core containing
gallotannins (GCGs)’. The ligand-enzyme interaction was studied using several biophysical
and spectroscopic tools including ITC, fluorescent probe and CD spectra. Our results
showed that these GCGs had a single binding site, they could decrease the hydrophobic
surfaces of the enzyme protein, and also reduce the α-helix conformation content of the
protein’s secondary structure. Our study provides valuable information underlying the
interactions between these GCGs and α-glucosidase, a crucial step towards further
investigating their potential as natural AGIs. Further investigation of these GCGs will focus
on in vivo studies to evaluate their safety and efficacy as potential dietary agents for T2DM
management which is included in our group’s future planned studies.
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Figure 1.

Chemical structures of five ‘glucitol core containing gallotannins (GCGs)’: ginnalin A,
ginnalin B, ginnalin C, maplexin F and maplexin J.
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Figure 2.
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Lineweaver-Burk plots of the kinetics of inhibition of GA (A), MF (B) and MJ (C) on αglucosidase enzyme. Two concentrations (ranging from 2 – 250 μM of ligands; close to their
IC50 values) were co-incubated with α-glucosidase at 37 °C for 30 min, then pNPG was
added at varying concentrations (from 1–1000 μM).
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Figure 3.

Results of isothermal titration calorimetry (ITC) for GCGs binding to α-glucosidase: (Top)
Raw data plot of heat flow against time for the titration of MF (A) or MJ (B) into 0.031 mM
α-glucosidase enzyme protein. (Bottom) Plot of molar enthalpy change against GCGs/αglucosidase enzyme molar ratio.
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Figure 4.
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Fluorescence intensity of bis-ANS-α-glucosidase complex. The changes of fluorescence
intensity were induced by GA (A), MF (B) and MJ (C) at different concentrations ranging
from 20 – 80 μM.
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Figure 5.
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Circular dichroism (CD) spectra of the α-glucosidase-GCG complex. α-glucosidase (2 μM)
were co-incubated with GA, MF, or MJ at 20–80 μM at 37 °C for 20 min.
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Figure 6.
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The properties of the refined α-glucosidase structure. (A) Ramachandran plot for a 3D
model of α-glucosidase (residues denoted with a + are outliers); (B) Time dependences of
the root mean square deviations (RMSD) of the backbone atoms (Cα, N, O-atoms) with
respect to initial structure.
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Figure 7.
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Top five potential ligand binding site generated via Site Finder module in MOE2010.10. The
binding site is represented by alpha sphere centers and red oval. The active site is comprised
of catalytic residues (Asp 214, Glu276, and Asp349).
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Figure 8.

Binding modes for GA (A), MF (B), MJ (C), and superimposition of the binding modes of
GA (red), MF (aquamarine blue), and MJ (blue). Hydrogen bonds are depicted by red dotted
lines. Red oval represents the active binding site.
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α-Glucosidase inhibitory activities of GCGs
Compound

# of galloyl group

IC50 (μM) a

Type of inhibition

ginnalin B (GB)

1

> 1000

n.d.

ginnalin C (GC)

1

> 1000

n.d.

ginnalin A (GA)

2

216.43 ± 3.19

noncompetitive

maplexin F (MF)

3

13.70 ± 0.87

noncompetitive

maplexin J (MJ)

4

4.27 ± 0.13

noncompetitive

acarbose b

—

142.40 ± 1.68

competitive

a

IC50 values are shown as mean ± S.D. from three independent experiments;

b

Positive control; n.d. = not determined.
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n.d.

1.01

1.01

GA

MF

MJ

n.d.: not detected

N [GCGs/α-glucosidase]

Ligand

4.22

2.85

n.d.

Ka[104 mol−1]

−6.31

−6.09

n.d.

ΔG [kJ mol−1]

−25.17

−10.26

n.d.

ΔH [kJ mol−1]

63.31

14.06

n.d.

ΔS [J mol−1 K−1]

Thermodynamic parameters for GCGs [ginnalin A (GA); maplexin F (MF) and maplexin J (MJ)] binding to α-glucosidase enzyme
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The effect of GCGs (GA, MF, and MJ) on the secondary structure of α-glucosidase enzyme
Ligands (Conc.)

α-Helix %

β-Fold %

β-Turns %

Unordered %

Control

36.3

21.9

14.3

26.9

GA 40 μM

37.8

22.7

11.5

27.8

GA 80 μM

33.5

22.5

15.8

27.7

MF 20 μM

30.7

24.7

15.6

28.4

MF 40 μM

31.2

22.7

16.6

28.9

MJ 20 μM

31.8

21.1

20.4

26.4

MJ 40 μM

30.7

24.4

19.1

25.3
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Detailed docking results for GA, MF, and MJ. Cluster represents the docking score of the lowest binding
energy conformation of the more populated cluster.
compound
Site 1

Site 2

Site 3

Site 4

Site 5

Range

GA

MF

MJ

(−17.59, −8.53)

(−19.87, −11.98)

(−21.70, −9.40)

cluster

−10.54

−12.02

−16.53

Range

(−12.57, −5.78)

(−12.56, −6.80)

(−13.77, −6.39)

cluster

−8.44

−8.15

−9.14

Range

(−16.11, −6.47)

(−18.20, −8.70)

(−19.47, −7.70)

cluster

−11.27

−12.25

−13.04

Range

(−14.41, −5.28)

(−17.37, −6.43)

(−15.03, −5.90)
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cluster

−10.26

−10.37

−9.86

Range

(−15.24, −7.46)

(−17.78, −6.23)

(−16.00, −7.53)

cluster

−11.32

−11.72

−11.06
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